48,830
edits
Line 40: | Line 40: | ||
**One benchmark is < 3-5% of biopsies.<ref name=THvdK>THvdK. 19 June 2010.</ref> | **One benchmark is < 3-5% of biopsies.<ref name=THvdK>THvdK. 19 June 2010.</ref> | ||
*Never diagnosed on excision, i.e. prostatectomy specimen. | *Never diagnosed on excision, i.e. prostatectomy specimen. | ||
*Cancers diagnosed after ASAP are not more frequently clinically significant, than cancers diagnosed after a diagnosis of benign or HGPIN.<ref name=pmid28888752>{{Cite journal | last1 = Wiener | first1 = S. | last2 = Haddock | first2 = P. | last3 = Cusano | first3 = J. | last4 = Staff | first4 = I. | last5 = McLaughlin | first5 = T. | last6 = Wagner | first6 = J. | title = Incidence of Clinically Significant Prostate Cancer After a Diagnosis of Atypical Small Acinar Proliferation, High-grade Prostatic Intraepithelial Neoplasia, or Benign Tissue. | journal = Urology | volume = 110 | issue = | pages = 161-165 | month = Dec | year = 2017 | doi = 10.1016/j.urology.2017.08.040 | PMID = 28888752 }}</ref> | |||
===Association with adenocarcinoma=== | ===Association with adenocarcinoma=== |
edits